Stay updated with breaking news from New Day Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC detection and compliance, potentially extending patient survival.
With more than 200,000 cases of colon cancer diagnosed across the country every year, researchers are working on new ways to detect the disease better.
/PRNewswire/ -- The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides,...
EQSAdhoc Epigenomics AG Key word Personnel Epigenomics AG Executive Board member Jens Ravens leaves the Company on April 30 2024 30Oct2023 1549 CETCEST Disclosure of an inside information acc to Arti
Epigenomics AG / Key word(s): PersonnelEpigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 202430-Oct-2023 / 15:49 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is so...